Molecular Biology of Bladder Cancer

Hematology/Oncology Clinics of North America

Volumn 29, Issue 2, 2015, Pages 191-203

  Martin Doyle, William ^a   Kwiatkowski, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bladder cancer; Cell cycle; Epigenetics; Molecular subtypes; Mutations; Somatic copy number alterations; Urothelial carcinoma

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E1; CYCLINE; MAMMALIAN TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MDM2; PROTEIN P21; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

BLADDER CANCER; CANCER GENETICS; CELL CYCLE PROGRESSION; COPY NUMBER VARIATION; CYTOMEGALOVIRUS INFECTION; EGFR GENE; EPIGENETICS; ERBB2 GENE; ERBB3 GENE; ERCC2 GENE; FGFR3 GENE; GENE; GENE AMPLIFICATION; GENE CLUSTER; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC CODE; HUMAN; LIPID METABOLISM; MOLECULAR BIOLOGY; MUSCLE INVASIVE BLADDER CANCER; ONCOGENE; OXIDATIVE STRESS; PAPILLOMAVIRUS INFECTION; PI3KCA GENE; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; PTEN GENE; REVIEW; STAG2 GENE; TSC1 GENE; ANIMAL; CELL TRANSFORMATION; METABOLISM; URINARY BLADDER NEOPLASMS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 84933676546     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.10.002     Document Type: Review

References (51)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. United States Food and Drug Administration. Hematology/oncology (cancer) approvals & safety notifications. 2014. Available at: . Accessed August 23, 2014. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm.
3. Parada L.F., Tabin C.J., Shih C., et al. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982, 297:474-478.
4. Esrig D., Spruck C.H., Nichols P.W., et al. P53 nuclear-protein accumulation correlates with mutations in the P53 gene, tumor grade, and stage in bladder-cancer. Am J Pathol 1993, 143:1389-1397.
5. Cote R.J., Dunn M.D., Chatterjee S.J., et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998, 58:1090-1094.
6. Hornigold N., Devlin J., Davies A.M., et al. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 1999, 18:2657-2661.
7. Cappellen D., De Oliveira C., Ricol D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999, 23:18-20.
8. Lopez-Knowles E., Hernandez S., Malats N., et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006, 66:7401-7404.
9. Platt F.M., Hurst C.D., Taylor C.F., et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009, 15:6008-6017.
10. Blaveri E., Brewer J.L., Roydasgupta R., et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005, 11:7012-7022.
11. Simon R., Burger H., Brinkschmidt C., et al. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. JPathol 1998, 185:345-351.
12. Richter J., Jiang F., Gorog J.P., et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997, 57:2860-2864.
13. Voorter C., Joos S., Bringuier P.P., et al. Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am J Pathol 1995, 146:1341-1354.
14. Kallioniemi A., Kallioniemi O.P., Citro G., et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer 1995, 12:213-219.
15. Forbes S.A., Bindal N., Bamford S., et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011, 39:D945-D950.
16. Goebell P.J., Knowles M.A. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010, 28:409-428.
17. Williamson M.P., Elder P.A., Shaw M.E., et al. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 1995, 4:1569-1577.
18. Knowles M.A. Molecular pathogenesis of bladder cancer. Int J Clin Oncol 2008, 13:287-297.
19. The Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507:315-322.
20. Gui Y., Guo G., Huang Y., et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011, 43:875-878.
21. Guo G.W., Sun X.J., Chen C., et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013, 45:1459-1463.
22. Cazier J.B., Rao S.R., McLean C.M., et al. Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat Commun 2014, 5:3756.
23. Kandoth C., McLellan M.D., Vandin F., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
24. Nik-Zainal S., Alexandrov L.B., Wedge D.C., Breast Cancer Working Group of the International Cancer Genome Consortium, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149:979-993.
25. Roberts S.A., Sterling J., Thompson C., et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell 2012, 46:424-435.
26. Hurst C.D., Fiegler H., Carr P., et al. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 2004, 23:2250-2263.
27. Richter J., Beffa L., Wagner U., et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998, 153:1615-1621.
28. Hoglund M., Sall T., Heim S., et al. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res 2001, 61:8241-8246.
29. Sidransky D., Von Eschenbach A., Tsai Y.C., et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991, 252:706-709.
30. Xu H.J., Cairns P., Hu S.X., et al. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 1993, 53:781-784.
31. Chellappan S.P., Hiebert S., Mudryj M., et al. The E2F transcription factor is a cellular target for the RB protein. Cell 1991, 65:1053-1061.
32. Singh D., Chan J.M., Zoppoli P., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
33. Williams S.V., Hurst C.D., Knowles M.A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013, 22:795-803.
34. Greulich H., Kaplan B., Mertins P., et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA 2012, 109:14476-14481.
35. Jaiswal B.S., Kljavin N.M., Stawiski E.W., et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2014, 25:543-544.
36. Rebouissou S., Bernard-Pierrot I., de Reynies A., et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 2014, 6:244ra91.
37. Iyer G., Hanrahan A.J., Milowsky M.I., et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338:221.
38. Wagle N., Grabiner B.C., Van Allen E.M., et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014, 4:546-553.
39. Shibata T., Ohta T., Tong K.I., et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008, 105:13568.
40. Zhou J.B.A., Yu Q., Chng W.J. TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms. Int J Biochem Cell Biol 2011, 43:1668-1673.
41. Tontonoz P., Graves R.A., Budavari A.I., et al. Adipocyte-specific transcription factor-ARF6 is a heterodimeric complex of 2 nuclear hormone receptors, PPAR-gamma and RXR-alpha. Nucleic Acids Res 1994, 22:5628-5634.
42. Taylor C.F., Platt F.M., Hurst C.D., et al. Frequent inactivating mutations of STAG2 inbladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum Mol Genet 2014, 23:1964-1974.
43. Balbas-Martinez C., Sagrera A., Carrillo-de-Santa-Pau E., et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet 2013, 45:1464-1469.
44. Solomon D.A., Kim J.S., Bondaruk J., et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 2013, 45:1428-1430.
45. Lehmann A.R. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev 2001, 15:15-23.
46. Van Allen E.M., Mouw K.W., Kim P., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014, 4:1140-1153.
47. Takata R., Katagiri T., Kanehira M., et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005, 11:2625-2636.
48. Choi W., Porten S., Kim S., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014, 25:152-165.
49. Damrauer J.S., Hoadley K.A., Chism D.D., et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 2014, 111:3110-3115.
50. Sjodahl G., Lauss M., Lovgren K., et al. Amolecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012, 18:3377-3386.
51. Sjodahl G., Lovgren K., Lauss M., et al. Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol 2013, 183:681-691.